References

- A Ramachandran, Joshi S, Yajnik C, Kumar P: Current Status of Diabetes in India. Supplement to JAPI, 2010, Vol – 58, page 7 – 10.
- A Mayer, Michael H, Peter V. Endogenous Hypoxia Markers: Case Not Proven. Advances in experimental medicine and biology, 2008. Vol – 614, page 127 – 136.
- Birnbaum R, Miller R, Morris J. An energetic tale of AMPK-independent effects of metformin. Journal of clinical investigation, 2010. Vol – 7, issue – 120, page 2267 – 2270.
- Bowker S, Majumdar S, Veugelers P, Johnson J. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006. Vol – 29, page 254–258.
- Chandel N, McClintock D, Feliciano C, Wood TM, Melendez JA, Rodriguez A, Schumacker P. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: a mechanism of O2 sensing. Journal of biological chemistry, 2000. Vol – 275,issue – 33, page 130 – 138
- Chen Y, Zhou K, Wang R. Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Journal of clinical investigation, 2009. Vol – 106, page 3907–12.
- Charles F, Burant J, Takeda L. Fructose Transporter in Human Spermatozoa and Small Intestine is GLUT5. Journal of Biological chemistry, 1992. Vol. 267, issue 21, page 14523 – 14526.

- Dalgard C, Mohyeldin A, Verma A**.** Endogenous 2-oxoacids differentially regulate expression of oxygen sensors: Biochemistry Journal, 2004. Vol. 380, issue 2, page 419 - 424.

- El-Mir V, Fontaine E, Avéret N, Rigoulet M, Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. Journal of biological chemistry, 2000. Vol. 275, issue 1, page 223 – 228.

- Evans J, Emslie A, Alessi D, Morris A. Metformin and reduced risk of cancer in diabetic patients British Medical Journa, 2005. Vol – 330, page 1304 – 1305.

- Fukumoto H, Imura H, Seino Y, Bell G. Characterization and expression of human HepG2/erythrocyte glucose-transporter gene. Diabetis, 1988. Vol. 37, issue – 5, page 657 – 661.

- Fu-Yen Chung Ming-Yii Huang, Ching-Sheng Yeh, Hui-Jen Chang, Tian-Lu Cheng, Li-Chen Yen, Jaw-Yuan Wang and Shiu-Ru Lin. GLUT1 gene is a potential hypoxic marker in colorectal cancer patients. Biomedical Journal, 2009. Vol – 241, issue 9, page 1471 – 1479.

- Gillan Libby. New Users of Metformin Are at Low Risk of incident cancer. Diabetis care,2009. Vol – 32, issue 9, page 1620 – 1625.

- Semenza G. Targeting HIF-1 for cancer therapy. National research on cancer, 2003. Vol - 3, issue – 10, page 721 – 732.

- Glucose metabolism and Cancer : Warburg effect. The Medical Biochemistry page, 2013.

- Issam Ben Sahra Yannick Le Marchand-Brustel, Jean-François Tanti, and Frédéric Bost Metformin in Cancer Therapy: A New Perspective for old anti-diabetic drug..Molecular Cancer Therapeutics, 2010. Vol. 9, issue 5, page 1092 – 1099.

- Konrad Keller, Marilyn Strube, and MikMe uecklerg. Functional Expression of the Human HepG2 and Rat Adipocyte Glucose Transporters in *Xenopus* Oocytes: Comparison of Kinetic parameters. Journal of Biological chemistry, 1989. Vol. 264, issue 32, page 18884 – 18889.

- Lewis Z. Shi Ruoning Wang, Gonghua Huang, Peter Vogel. HIF1α–dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of T_H17 and T_{reg} cells. Journal of experimental medicine, 2011. Vol. 208, issue – 7, page 1367 – 1377.

- Lo´pez-La´zaro1 Miguel. HIF-1: hypoxia-inducible factor or dysoxia-inducible factor. The FASEB journal, 2006. Vol – 6, page 828 – 832.

- Lu H Dalgard CL, Mohyeldin A, McFate T, Tait AS, Verma A. Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. Journal of Biological chemistry, 2005. Vol. 280, issue – 51, page 41928 – 41938.

- Lu H Forbes R, Verma A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. Journal of Biological chemistry, 2002. Vol - 277, issue – 26, page 23111 – 23115.

- Makoto Endo Ukihide Tateishi, Kunihiko Seki, Umio Yamaguchi, Fumihiko Nakatani, Akira Kawai, Hirokazu Chuman and Yasuo Beppu. Prognostic Implications of Glucose Transporter Protein-1 (Glut-1) Overexpression in Bone and Soft-Tissue Sarcomas. Journal of clinical oncology, 2007. Vol – 37, issue - 12, page 955 – 960.

- Marc Foretz Sophie Hébrard, Jocelyne Leclerc, Elham Zarrinpashneh, Maud Soty, Gilles Mithieux, Kei Sakamoto, Fabrizio Andreelli and Benoit Viollet. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. Journal of clinical investigation, 2010. Vol – 120, issue – 7, page 2355 – 2369.

- Mois´es Blanco Calvo Ang´elica Figueroa, Enrique Grande Pulido. Potential Role of Sugar Transporters in Cancer and Their Relationship with Anticancer Therapy. International Journal of Endocrinology, 2010. Vol – 2010, page 1 – 14.

- Noguchi Yoshikazu. Suppression of facilitative glucose transporter 1 mRNA can suppress tumor growth. Cancer letters, 2000. Vol – 154, issue – 2, page 175 – 182.

- Paolo Vigneri Francesco Frasca, Laura Sciacca, Giuseppe Pandini. Diabetes and cancer. Endocrine related cancer Journal, 2009. Vol – 16, page 1103 – 1123.

- Patel Trushar. Clinical Outcomes After Radical Prostatectomy in Diabetic Patients Treated With Metformin. urology, 2010. Vol. 76, issue – 5, page 1240 – 1244.

- Qingqiong Luo Dan Hu, Shuiqing Hu, Ming Yan, Zujun Sun and Fuxiang Chen. In vitro and in vivo anti-tumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma. BMC cancer, 2012. Vol – 12, issue – 517, page 1 – 10.

- Raffaele Ciampia Agnese Vivaldia, Cristina Romeia, Alberto Del Guerrab, d, Piero Salvadoric, Barbara Coscia, Aldo Pincheraa, d, Rossella Elisei. Expression analysis of facilitative glucose transporters (GLUTs) in human thyroid carcinoma cell lines and primary tumors. Molecular and cellular endocrionology, 2008. Vol – 291, issue – 2, page 57 – 62.

- Rvan J, Goodwin P, Stambolic V. Understanding the benefit of metformin use in cancer treatment . Biomedical Journal, 2011. Vol – 33, issue – 9, page 1741 – 1746.

- Sao Jiralerspong Shana L. Palla, Sharon H. Giordano, Funda Meric-Bernstam, Cornelia Liedtke, Chad M. Barnett, Limin Hsu, Mien-Chie Hung, Gabriel N. Hortobagyi and Ana M. Gonzalez-Angulo. Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer. Journal of clinical oncology, 2009. Vol – 27, issue 20, page 3297 – 3302.

- Shao SL Cai Y, Wang QH, Yan LJ, Zhao XY, Wang LX. Expression of GLUT-1, p63 and DNA-Pkcs in serous ovarian tumors and their significance. Chinese Journal of Oncology, 2007. Vol. 29, issue – 9, page 697 – 700.

- Vogelstein B, Kinzler K. Cancer genes and the pathways they control. National medicine, 2004. Vol. 10, issue – 8, page 789 – 799.

- Zhou G Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action. Journal of Clinical Investigation, 2001. Vol – 108, issue 8, page 1167 – 1174.